Compare 10X Genomics Inc (TXG) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Western Alliance Bancorporation — how do they compare? 10X Genomics Inc trades at $78.6 (market cap $9.92B), while Western Alliance Bancorporation trades at $76.21 (market cap $8.11B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and Western Alliance Bancorporation pays a 2.26% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Western Alliance Bancorporation for 3 Days on average.
| TXG | WAL | |
|---|---|---|
Market Cap | $9.92B | $8.11B |
Volume | 9,372,166 | 1,479,953 |
Sector | Health | Financials |
52-Week High | $97.74 | $96.08 |
52-Week Low | $11.48 | $66.70 |
Typical Hold Time | 92 Days | 3 Days |
Enterprise Value | $9.44B | $9.63B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Western Alliance Bancorporation (WAL) trades at $74.35, down 2.29% on the day, with a bearish technical outlook despite strong fundamentals. The company maintains robust profitability with 25.43% net income margin and 13.43% ROE, supported by recent earnings beats in Q4 2025 and Q1 2026. Recent developments include the launch of WA VenueX digital asset platform and participation in major financial conferences, while institutional investors show mixed positioning.
WAL presents a compelling value opportunity with attractive valuation multiples (P/E 8.39, P/B 1.07) and strong analyst support (79% buy ratings, $84.33 consensus target). However, near-term risks include the recent Q2 2026 EPS miss, bearish technical indicators, and regulatory uncertainty around Fed policy changes affecting bank asset thresholds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
